Chong-Rui Xu

机构：Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Southern Medical University, South China University of Technology

发表论文 8 篇 · 总被引 5 次 · h-index 1

代表论文

Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS) (2026 · Nature Communications · 被引 5)
PP01.42: Efficacy and Multi-omics Insights of Immune Checkpoint Inhibitors in NSCLC with Leptomeningeal Metastasis (2026 · Journal of Thoracic Oncology)
PP01.54: The Outcome of Pemigatinib in Advanced NSCLC With A Novel FGFR Fusion: Case Report (2026 · Journal of Thoracic Oncology)
PP01.01: Association and Prognosis of Non-Cancerous Respiratory Diseases to Lung Cancer and Pan-Cancer: Observational and Mendelian Randomization Analysis (2026 · Journal of Thoracic Oncology)
Additional file 1: Table S1. of Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial (2016 · Figshare)
Additional file 2: of Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial (2016 · Figshare)